HUP0002597A2 - Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására - Google Patents
Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására Download PDFInfo
- Publication number
- HUP0002597A2 HUP0002597A2 HU0002597A HUP0002597A HUP0002597A2 HU P0002597 A2 HUP0002597 A2 HU P0002597A2 HU 0002597 A HU0002597 A HU 0002597A HU P0002597 A HUP0002597 A HU P0002597A HU P0002597 A2 HUP0002597 A2 HU P0002597A2
- Authority
- HU
- Hungary
- Prior art keywords
- fraction
- treatment
- lipid
- blood
- plasma
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 210000002381 plasma Anatomy 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 230000008569 process Effects 0.000 title abstract description 5
- 150000002632 lipids Chemical class 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 51
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 42
- 241000283690 Bos taurus Species 0.000 claims abstract description 30
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims abstract description 13
- 238000005119 centrifugation Methods 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 4
- 239000010419 fine particle Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 241000306001 Cetartiodactyla Species 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 24
- 238000002955 isolation Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 239000000463 material Substances 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 9
- 206010000830 Acute leukaemia Diseases 0.000 description 8
- 230000002349 favourable effect Effects 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102000004008 5'-Nucleotidase Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000005741 malignant process Effects 0.000 description 3
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
| BRPI0112866 BR0112866A2 (en, 2012) | 2000-07-10 | 2001-07-10 | |
| MXPA03000342A MXPA03000342A (es) | 2000-07-10 | 2001-07-10 | Preparacion farmaceutica para el tratamiento y diagnostico de tumores y metodos para la preparacion de la fraccion libre de lipido de plasma sanguineo. |
| JP2002513472A JP2004504353A (ja) | 2000-07-10 | 2001-07-10 | 腫瘍の処置及び診断のための医薬調製物並びに血漿の無脂質画分の調製方法 |
| CNA018139744A CN1477965A (zh) | 2000-07-10 | 2001-07-10 | 用于肿瘤治疗和诊断的药物制品及制备血浆无脂质部分的方法 |
| YU9903A YU9903A (sh) | 2000-07-10 | 2001-07-10 | Jedinjenja za vodenu stabilizaciju vitamina rastvorljivih u mastima |
| PCT/HU2001/000078 WO2002007739A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| AU2001277630A AU2001277630A1 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| HR20030098A HRP20030098A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| US10/332,440 US20040253317A1 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| KR10-2003-7000393A KR20030016392A (ko) | 2000-07-10 | 2001-07-10 | 종양의 치료 및 진단을 위한 약학적 제조물과 혈장의 지질유리된 부분의 제조 방법 |
| CA002415862A CA2415862A1 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| IL15386701A IL153867A0 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| PL01361049A PL361049A1 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| EP01955468A EP1333844A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| EA200300133A EA005415B1 (ru) | 2000-07-10 | 2001-07-10 | Фармацевтический препарат для лечения, профилактики и/или диагностики опухолей и способ получения его активного компонента |
| SK128-2003A SK1282003A3 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| ZA200300675A ZA200300675B (en) | 2000-07-10 | 2003-01-24 | Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma. |
| BG107547A BG107547A (bg) | 2000-07-10 | 2003-02-10 | Фармацевтичен препарат за лечение и диагноза на тумори и метод за получаване на липидночиста фракция от кръвна плазма |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU0002597D0 HU0002597D0 (en) | 2000-09-28 |
| HUP0002597A2 true HUP0002597A2 (hu) | 2003-01-28 |
Family
ID=89978459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040253317A1 (en, 2012) |
| EP (1) | EP1333844A2 (en, 2012) |
| JP (1) | JP2004504353A (en, 2012) |
| KR (1) | KR20030016392A (en, 2012) |
| CN (1) | CN1477965A (en, 2012) |
| AU (1) | AU2001277630A1 (en, 2012) |
| BG (1) | BG107547A (en, 2012) |
| BR (1) | BR0112866A2 (en, 2012) |
| CA (1) | CA2415862A1 (en, 2012) |
| EA (1) | EA005415B1 (en, 2012) |
| HR (1) | HRP20030098A2 (en, 2012) |
| HU (1) | HUP0002597A2 (en, 2012) |
| IL (1) | IL153867A0 (en, 2012) |
| MX (1) | MXPA03000342A (en, 2012) |
| PL (1) | PL361049A1 (en, 2012) |
| SK (1) | SK1282003A3 (en, 2012) |
| WO (1) | WO2002007739A2 (en, 2012) |
| YU (1) | YU9903A (en, 2012) |
| ZA (1) | ZA200300675B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200172A2 (hu) | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| GB2405540B (en) * | 2003-08-27 | 2006-05-10 | Ron Shu-Yuen Hui | Apparatus and method for providing dimming control of lamps and electrical lighting systems |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791142A (en) * | 1954-09-22 | 1958-02-26 | Atsuwo Ushiyama | A process for preparing antibiotic substance from special bacterium in human blood plasma and earth |
| GB834256A (en) * | 1955-08-18 | 1960-05-04 | Olin Mathieson | Therapeutic bone mixture |
| US3083194A (en) * | 1959-05-18 | 1963-03-26 | Thies Karl | Montmorillonite adsorption of fibrin from bovine blood plasma |
| JPS5357191A (en) * | 1976-11-04 | 1978-05-24 | Asahi Chem Ind Co Ltd | Activated carbon for adsorption of toxin in serum |
| NL9001087A (nl) * | 1990-05-07 | 1991-12-02 | Harimex Ligos Bv | Werkwijze voor het zuiveren van bloedplasma. |
| RO111332B1 (ro) * | 1991-06-17 | 1996-09-30 | Inst De Cercetari Chimico Farm | Procedeu de obținere a unui produs hepatoprotector |
| HUP9900045A3 (en) * | 1999-01-08 | 2001-02-28 | Martyn Robertne Goeroeg Jolan | Improved leukaemic blood-based product and their use in therapy |
-
2000
- 2000-07-10 HU HU0002597A patent/HUP0002597A2/hu unknown
-
2001
- 2001-07-10 EA EA200300133A patent/EA005415B1/ru not_active IP Right Cessation
- 2001-07-10 US US10/332,440 patent/US20040253317A1/en not_active Abandoned
- 2001-07-10 WO PCT/HU2001/000078 patent/WO2002007739A2/en not_active Application Discontinuation
- 2001-07-10 PL PL01361049A patent/PL361049A1/xx unknown
- 2001-07-10 IL IL15386701A patent/IL153867A0/xx unknown
- 2001-07-10 JP JP2002513472A patent/JP2004504353A/ja active Pending
- 2001-07-10 AU AU2001277630A patent/AU2001277630A1/en not_active Abandoned
- 2001-07-10 MX MXPA03000342A patent/MXPA03000342A/es unknown
- 2001-07-10 CA CA002415862A patent/CA2415862A1/en not_active Abandoned
- 2001-07-10 SK SK128-2003A patent/SK1282003A3/sk unknown
- 2001-07-10 CN CNA018139744A patent/CN1477965A/zh active Pending
- 2001-07-10 KR KR10-2003-7000393A patent/KR20030016392A/ko not_active Withdrawn
- 2001-07-10 HR HR20030098A patent/HRP20030098A2/hr not_active Application Discontinuation
- 2001-07-10 BR BRPI0112866 patent/BR0112866A2/pt not_active Application Discontinuation
- 2001-07-10 YU YU9903A patent/YU9903A/sh unknown
- 2001-07-10 EP EP01955468A patent/EP1333844A2/en not_active Withdrawn
-
2003
- 2003-01-24 ZA ZA200300675A patent/ZA200300675B/xx unknown
- 2003-02-10 BG BG107547A patent/BG107547A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030016392A (ko) | 2003-02-26 |
| JP2004504353A (ja) | 2004-02-12 |
| PL361049A1 (en) | 2004-09-20 |
| AU2001277630A1 (en) | 2002-02-05 |
| CA2415862A1 (en) | 2002-01-31 |
| EP1333844A2 (en) | 2003-08-13 |
| HRP20030098A2 (en) | 2004-08-31 |
| SK1282003A3 (en) | 2003-08-05 |
| EA005415B1 (ru) | 2005-02-24 |
| HU0002597D0 (en) | 2000-09-28 |
| WO2002007739A9 (en) | 2003-10-16 |
| WO2002007739A3 (en) | 2002-10-10 |
| WO2002007739A2 (en) | 2002-01-31 |
| CN1477965A (zh) | 2004-02-25 |
| YU9903A (sh) | 2006-05-25 |
| MXPA03000342A (es) | 2004-12-13 |
| IL153867A0 (en) | 2003-07-31 |
| US20040253317A1 (en) | 2004-12-16 |
| BR0112866A2 (en, 2012) | 2009-12-08 |
| BG107547A (bg) | 2004-01-30 |
| EA200300133A1 (ru) | 2003-06-26 |
| ZA200300675B (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farber | Chemotherapy in the treatment of leukemia and Wilms' tumor | |
| Botnick et al. | Limited proliferation of stem cells surviving alkylating agents | |
| JP2000500124A (ja) | ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬 | |
| US20140329322A1 (en) | Method of differentiating glioblastoma cells | |
| US20030149011A1 (en) | Methods and reagents for extracorporeal immunomodulatory therapy | |
| HUP0002597A2 (hu) | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására | |
| Hellstr6m et al. | Cellular immunity against tumor antigens | |
| JPH07505893A (ja) | 免疫学的機能不全を伴う疾患の治療のための方法および組成物 | |
| Yamamura et al. | Uncomplicated HL-A matched sibling bone marrow graft for combined immune deficiency | |
| US20160375060A1 (en) | Methods of Treating Glioblastoma Multiforme by T Cell Therapy | |
| RU2364404C2 (ru) | Биологически активная сыворотка крови, способы ее получения и ее применение | |
| WO1995025531A1 (en) | Means for treating auto-immune diseases and method of treatment | |
| Mariani et al. | Blood Tumors and Their Therapies | |
| Vose | Mantle cell lymphoma: minimal residual disease outcomes | |
| Nitze et al. | Synchronisation of Human Tissues and its Consequences for Cancer Therapy in ENT | |
| Okunewick et al. | Rauscher leukemia as a model for studies of marrow transplantation therapy: Results using syngeneic, allogeneic and hybrid donors | |
| Goodrich et al. | Formulating Autologous Therapies for Cancer | |
| JAMES | Tumor immunology and response to radiation therapy | |
| Kumukova et al. | Standard extracorporeal photopheresis for the treatment of graft-versus-host disease: Single-center study results | |
| KÔSAKI et al. | On Malignolipin. IX An Antigenic (Haptenic) Property of Malignolipin | |
| US4931431A (en) | Arthritis treatment with hypoxanthine | |
| RU2200547C2 (ru) | Препарат для лечения гепатоза животных | |
| WO1988001870A1 (en) | Therapeutic treatment for arthritic conditions | |
| Smit Sibinga et al. | Discussion: Moderators: G. Opelz, DW van Bekkum | |
| DeVita | Cancer Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |